Background:
Cancer along with cardiovascular diseases are globally defined as leading causes of death.
Importantly, some risk factors are common to these diseases. The process of angiogenesis and platelets aggregation are
observed in cancer development and progression. In recent years, studies have been conducted on nanodrugs in these
diseases that have provided important information on the biological and physicochemical properties of nanoparticles. Their
attractive features are that they are made of biocompatible, well-characterized and easily functionalized materials. Unlike
conventional drug delivery, sustained and controlled drug release can be obtained by using nanomaterials.
Methods:
In this article, we review the latest research to provide comprehensive information on nanoparticle-based drugs
for the treatment of cancer, cardiovascular disease associated with abnormal haemostasis, and the inhibition of tumorassociated angiogenesis.
Results:
The results of the analysis of data based on nanoparticles with drugs confirm their improved pharmaceutical and
biological properties, which gives promising antiplatelet, anticoagulant and antiangiogenic effects. Moreover, the review
included in vitro, in vivo research and presented nanodrugs with chemotherapeutics approved by Food and Drug
Administration.
Conclusion:
By the optimization of nanoparticles size and surface properties, nanotechnology are able to deliver drugs with
enhanced bioavailability in treatment of cardiovascular disease, cancer and inhibition of cancer-related angiogenesis. Thus,
nanotechnology can improve the therapeutic efficacy of the drug, but there is a need for a better understanding of the
nanodrugs interaction in the human body, because this is a key factor in the success of potential nanotherapeutics.